Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OCSAW by emailGet an email when OCSAW pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OCSAW, unsubscribe in one click. Privacy
📣 What OCSAW Says Is Next
this year · “This transaction comes at an opportune time, as Privosegtor is advancing rapidly through key regulatory milestones, including the ongoing PIONEER-1 registrational trial for optic neuritis and an expected IND submission for acute MS relapse later this year.”
Company press release, Aug 10, 2026 · SEC filing
late 2026 · “In 2025, following a successful FDA alignment meeting, we initiated the registrational PREDICT-1 trial in DED, with topline results anticipated around late 2026.”
Company press release, Apr 21, 2026 · SEC filing
Q4 2026 · “Topline results from PREDICT-1 are expected in Q4 2026.”
Company press release, Mar 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OCSAW picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCSAW and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.